Envelope‐Specific Antibodies in the Saliva of Individuals Vaccinated With Recombinant HIV‐1 gp160
Envelope‐Specific Antibodies in the Saliva of Individuals Vaccinated With Recombinant HIV‐1 gp160
复制标题
接种重组 HIV-1 gp160 的个体唾液中的包膜特异性抗体
DOI：
--
复制
发表时间：
1992
期刊：
影响因子：
--
通讯作者：
N. Salzman
中科院分区：
文献类型：
--
作者：
M. Vasudevachari;K. Uffelman;Joseph Kovacs;C. Yeh;H. Lane;N. Salzman
在血清阳性个体的唾液中检测到hiv -1特异性抗体，可能在预防病毒的口服传播中起作用。我们分析了HIV-1血清阴性个体的唾液样本，这些个体接种了不同剂量的重组HIV-1包膜糖蛋白（gp160）疫苗，以检测HIV-1抗体的存在。在所有志愿者的唾液中检测到包膜糖蛋白特异性抗体，接种较高剂量640和1280 μg疫苗的志愿者表现出最强的反应。接种后4-14周唾液抗体滴度达到峰值；然后随着血清抗体滴度逐渐下降。这些包膜特异性抗体在全唾液和下颌下唾液中检测到，而在腮腺唾液中未检测到，提示唾液中抗体的来源是血清转译。反应性抗体为IgG。接种疫苗个体唾液中的HIV-1特异性抗体可能提供局部保护以抵抗HIV-1感染。
HIV-1-specific antibodies have been detected in the saliva of sero-positive individuals and may play a role in preventing oral transmission of the virus. We have analyzed saliva samples obtained from HIV-1-seronegative individuals who were immunized with various dosages of a recombinant HIV-1 envelope glycoprotein (gp160) vaccine for the presence of antibodies to HIV-1. Antibodies specific for envelope glycoproteins were detected in saliva from all of the volunteers, with those vaccinated with the higher doses of 640 and 1,280 μg showing the strongest responses. Peak salivary antibody titers were obtained 4–14 weeks after vaccination; they then gradually dropped in parallel with serum antibody titers. These envelope-specific antibodies were detected in whole saliva and in submandibular saliva but not in parotid saliva, suggesting that the source of antibodies in saliva is from serum transudation. The class of reactive antibodies was found to be IgG. The HIV-1-specific antibodies in the saliva of vaccinated individuals may offer local protection against HIV-1 infection.